Loading...
•
Mar 31, 2020
Savara Q1 2020 Earnings Report
Reported financial results for the first quarter ending March 31, 2020 and provided a business update.
Key Takeaways
Savara reported a net loss attributable to common stockholders of $15.4 million, or $(0.27) per share, for the three months ended March 31, 2020. As of March 31, 2020, Savara had cash, cash equivalents, and short-term investments of approximately $105 million.
Announced expected design for IMPALA 2, the next Phase 3 study of Molgradex in aPAP.
Obtained global rights to develop and commercialize Apulmiq (inhaled ciprofloxacin) for non-cystic fibrosis bronchiectasis (NCFB).
Closed enrollment in the Phase 3 AVAIL study of AeroVanc for methicillin-resistant Staphylococcus aureus (MRSA) lung infection due to COVID-19 concerns, with top line results expected in early 2021.
Closed enrollment in the Phase 2a ENCORE study of Molgradex for nontuberculous mycobacterial (NTM) lung infection due to COVID-19 concerns.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...